luminal B型晚期乳腺癌临床病理特征及预后分析

发布时间：2018-04-01 18:51

本文选题：乳腺癌　切入点：分子分型　出处：《中国肿瘤临床》2017年04期

【摘要】：目的:探讨luminal B型晚期乳腺癌患者的临床病理特征及预后因素。方法:收集2008年6月至2013年6月天津医科大学肿瘤医院收治的206例luminal B型晚期乳腺癌患者的临床资料,回顾性分析其临床病理特征及影响预后的因素。结果:206例患者中HER-2阳性型54例(26.2%),HER-2阴性型152例(73.8%)。其中HER-2阳性型患者中Ki-6730%为57.4%(31/54),较HER-2阴性型的55.9%(85/152)高,差异具有统计学意义(P0.01);HER-2阳性型患者中无病生存期(disease free survival,DFS)36个月为79.6%(43/54),较HER-2阴性型的65.1%(99/152)高,差异具有统计学意义(P0.05)。206例患者的中位生存期为25(2.1~85.0)个月,是否合并内脏转移、一线解救化疗疗效、是否行解救内分泌治疗是luminal B型晚期乳腺癌患者的独立预后因素(P0.05)。结论:luminal B型晚期乳腺癌患者中,HER-2阳性型中的Ki-67指数比HER-2阴性型更高,且更易在3年内发生复发、转移。合并内脏转移、一线解救化疗时病情进展、未行解救内分泌治疗是影响luminal B型晚期乳腺癌患者不良预后的独立因素。
[Abstract]:Objective: to investigate the clinicopathological features and prognostic factors of luminal B type advanced breast cancer.Methods: the clinical data of 206 patients with advanced luminal B breast cancer admitted to Tianjin Medical University Cancer Hospital from June 2008 to June 2013 were retrospectively analyzed and their clinicopathological features and prognostic factors were analyzed retrospectively.Results among the 206 patients, 54 were HER-2 positive and 152 were HER-2 negative.The difference was statistically significant in the median survival time of P0.05. 206 patients with advanced luminal B breast cancer. Whether the patients had visceral metastasis, first-line chemotherapeutic effect and endocrine rescue therapy was the independent prognostic factor of luminal B type advanced breast cancer.Conclusion the Ki-67 index of HER-2 positive type is higher than that of HER-2 negative type in patients with advanced breast cancer of type B, and it is more likely to recur and metastasize within 3 years.The patients with visceral metastasis, first-line rescue chemotherapy and no rescue endocrine therapy were independent factors influencing the poor prognosis of patients with luminal B type advanced breast cancer.
【作者单位】：天津医科大学肿瘤医院乳腺肿瘤内科国家肿瘤临床医学研究中心乳腺癌防治教育部重点实验室天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心;
【基金】：国家科技支撑计划项目(编号:2015BAI12B00)资助~~
【分类号】：R737.9

【相似文献】